New drug could delay cancer in High-Risk patients
NCT ID NCT07393282
First seen Feb 06, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tests if a new drug, linvoseltamab, can delay the development of active multiple myeloma better than an existing drug, daratumumab, in people with smoldering multiple myeloma who are at high risk. About 270 participants will be randomly assigned to one of the two treatments. The goal is to see which drug keeps the cancer from progressing longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.